# Therna Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/therna-biosciences

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.therna.com
- Total disclosed funding: $9.2M
- Latest round: Seed (Aug 26, 2025)
- Investors on record: 3

## About

Based in California, US, and founded in 2023, Therna Biosciences specializes in programmable RNA therapeutics. In August 2025, Therna Biosciences raised USD 9.21 million in seed funding from new investors AIX Ventures, Pear VC, and Fusion Fund. Other unspecified investors also participated in the round. Co-founded by Nazli Azimi (CEO), Hani Goodarzi, and Sasan Amini.

Therna specializes in the development of programmable RNA therapeutics through its proprietary generative RNA design platform. This innovative platform integrates deep RNA biology with generative artificial intelligence, allowing for the creation of custom mRNA sequences that can express, silence, or fine-tune gene activity. The main applications of these products include therapeutic interventions for diseases that traditional drug modalities have struggled to address, providing targeted solutions in areas like oncology, genetic disorders, and infectious diseases. The company's technology enables researchers and pharmaceutical companies to quickly and precisely design RNA-based medicines tailored to specific therapeutic needs, primarily utilized in North America and Europe.

Therna has established a revenue model centered on partnerships with pharmaceutical companies and research institutions, focusing on B2B transactions that leverage their unique RNA design capabilities. These engagements typically involve collaborations or licensing agreements allowing clients to access Therna's platform for developing custom RNA therapeutics. Additionally, subscription-based arrangements may provide ongoing access to their technology, creating a continuous revenue stream from both large pharmaceutical enterprises and smaller biotech firms, with pricing based on the scope and complexity of services utilized. 

The company plans to use the August 2025 funding to improve the development of its RNA-based medications.

## Funding rounds

- Seed, Aug 26, 2025, $9.2M — Pear VC, Fusion Fund, AIX Ventures

## Investors

- Pear VC (https://capitalatlas.ai/funds/pear-vc) — Seed
- Fusion Fund (https://capitalatlas.ai/funds/fusion-fund) — Seed
- AIX Ventures (https://capitalatlas.ai/funds/aix-ventures) — Seed